Clinical and Economic Aspects of Hormonotherapy Er (+) Her2 (–) Breast Cancer (Bc): Focus on Aromatase Inhibitors (Ai)

Abstract

Aim. Analysis of clinical efficacy of AI for therapy ER (+) HER2 (–) BC, assortment and volume of their consumption in Ukraine in 2017–2020. Materials and methods. Analysis of the assortment and prices and consumption of AI for hormone therapy ER (+) HER2 (–) BC, available on the pharmaceutical market of Ukraine in 2017–2020. Results. A retrospective analysis of the assortment, prices and consumption of AI used for therapy ER (+) HER2 (–) BC, presented on the Ukrainian pharmaceutical market in 2017–2020, was carried out. AI were represented by 3 INNs: anastrozole (L02B G03), letrozole (L02B G04) and exemestane (L02B G06). Market prices in 2017 range from 460.5 to 4163.8; in 2018 – from 486.3 to 1849.0; in 2019 – from 308.7 to 1677.0; and in 2020 – from UAH 449.6 to UAH 2545.3. IA implemented in 2017 – 55,943, in 2018 – 81,284, in 2019 – 126,628, and in 2020 – 160,858.4 thousand packages. Conclusion. There is a clear tendency towards stabilization and even a decrease in prices for AI, if we compare the indicators of 2017 and 2020. There is a clear upward trend in consumption AI are implemented mainly of import production. The price picture for AI has changed somewhat due to the registration of drugs from the letrozole group in 2019-2020, and in 2020 – from the exemestane group.